Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.
作者： Tolia M , Tsoukalas N , Kostakis Id , Ardavanis A , Tzovaras Aa
DOI:
关键词: Epidermal growth factor receptor 、 Internal medicine 、 KRAS 、 Meta-analysis 、 Colorectal cancer 、 Oncogene 、 Oncology 、 Wild type 、 Cetuximab 、 Medicine 、 Publication bias
摘要: PURPOSE The monoclonal antibody cetuximab that targets epidermal growth factor receptor (EGFR) has been found effective in the treatment of colorectal cancer. However, mutations exons 12 and 13 KRAS oncogene have reported as negative predictive factors for response using cetuximab. purpose this study was to conduct a meta-analysis published studies investigating value efficacy patients suffering from METHODS A systematic search literature performed PubMed, Medline, Cochrane databases. Sensitivities, specificities values (negative positive) regards were calculated. RESULTS Twenty-six initially during search. After thorough evaluation, papers excluded various reasons. Therefore, included present meta-analysis. In these studies, much higher than sensitivities. Combining data it comprise biomarker with very high specificity (0.96; 95% CI 0.84-0.99), low sensitivity (0.47; 0.43-0.50). Finally, publication bias statistically significant. CONCLUSION results suggest should be administered only cancer who wild type (KRASw) oncogene. Mutations gene are sensitivity. latter may well attributed additional mechanisms resistance anti-EGFR therapies such BRAF.
参考文章(37)
Marcos Malumbres, Mariano Barbacid, RAS oncogenes: the first 30 years Nature Reviews Cancer. ,vol. 3, pp. 459- 465 ,(2003) , 10.1038/NRC1097
Petra Macaskill, Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis Journal of Clinical Epidemiology. ,vol. 57, pp. 925- 932 ,(2004) , 10.1016/J.JCLINEPI.2003.12.019
Afina S. Glas, Jeroen G. Lijmer, Martin H. Prins, Gouke J. Bonsel, Patrick M.M. Bossuyt, The diagnostic odds ratio: a single indicator of test performance Journal of Clinical Epidemiology. ,vol. 56, pp. 1129- 1135 ,(2003) , 10.1016/S0895-4356(03)00177-X
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
L.R. Arends, T.H. Hamza, J.C. van Houwelingen, M.H. Heijenbrok-Kal, M.G.M. Hunink, T. Stijnen, Bivariate random effects meta-analysis of ROC curves. Medical Decision Making. ,vol. 28, pp. 621- 638 ,(2008) , 10.1177/0272989X08319957
W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496
M Frattini, P Saletti, E Romagnani, V Martin, F Molinari, M Ghisletta, A Camponovo, L L Etienne, F Cavalli, L Mazzucchelli, PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer. ,vol. 97, pp. 1139- 1145 ,(2007) , 10.1038/SJ.BJC.6604009
Lincoln E. Moses, David Shapiro, Benjamin Littenberg, Combining independent studies of a diagnostic test into a summary roc curve: Data‐analytic approaches and some additional considerations Statistics in Medicine. ,vol. 12, pp. 1293- 1316 ,(1993) , 10.1002/SIM.4780121403
F. Perrone, A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, L. Bertario, E. Leo, M.A. Pierotti, S. Pilotti, PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Annals of Oncology. ,vol. 20, pp. 84- 90 ,(2008) , 10.1093/ANNONC/MDN541
Mirian Brink, Anton FPM de Goeij, Matty P Weijenberg, Guido MJM Roemen, Marjolein HFM Lentjes, Marco MM Pachen, Kim M Smits, Adriaan P de Bruïne, R Alexandra Goldbohm, Piet A van den Brandt, None, K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. ,vol. 24, pp. 703- 710 ,(2003) , 10.1093/CARCIN/BGG009